Share This Author
CIP2A is a target of bortezomib in human triple negative breast cancer cells
- L. Tseng, Chun-Yu Liu, Kung-Chi Chang, P. Chu, C. Shiau, Kuen-Feng Chen
- Biology, MedicineBreast Cancer Research
- 26 April 2012
CIP2A is a major determinant mediating bortezomib-induced apoptosis in TNBC cells and may be a potential therapeutic target in T NBC, which currently has no specific therapeutic targets.
Treatment of Liver Cancer.
- Chun-Yu Liu, Kuen-Feng Chen, Pei-Jer Chen
- Medicine, BiologyCold Spring Harbor perspectives in medicine
- 1 September 2015
This work focuses on reviewing the incidence, staging, and treatment of liver cancer, and there are variations in the management recommendations for liver cancers across specialties and geographic regions.
Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3
Dovitinib induces significant apoptosis in HCC cells and sorafenib-resistant cells via SHP-1–mediated inhibition of STAT3, suggesting that targeting STAT3 may be a useful approach to overcome drug resistance in H CC.
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
It is considered that multiple gene sequencing in cancer risk assessment is clinically valuable and testing for multiple cancer-predisposing genes is now being considered.
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
This study provided a preclinical rationale in selecting patients who might have therapeutic benefit from combining CDK4/6 inhibitors with AR antagonists and showed inhibitory effect in RB-proficient TNBC cells, and enzalutamide inhibited cell viability in AR-positive T NBC cells.
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells
The data suggest a novel “off-target“ mechanism of tamoxifen and suggest that CIP2A/PP 2A/p-Akt signaling may be a feasible anti-cancer pathway.
Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma
It is reported that Src homology region 2 (SH2) domain‐containing phosphatase 1 (SHP‐1) is a major target of sorafenib and a series of sorAFenib derivatives are generated to search for potent SHp‐1 agonists that may act as better anti‐HCC agents than sorafinib.
Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients
Breast cancer subtypes are associated with differing risks of brain metastasis among different age groups, and patients age 35 or younger are particularly at risk ofbrain metastasis independent of biological subtype.
Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation*
- Hui-Chuan Yu, Chen-Si Lin, W. Tai, Chun-Yu Liu, C. Shiau, Kuen-Feng Chen
- Biology, MedicineThe Journal of Biological Chemistry
- 15 May 2013
The data indicate that nilotinib-induced AM PK activation is mediated by PP2A, and AMPK activation and subsequent autophagy might be a major mechanism of action ofnilotinib.